1. Home
  2. TRVI vs KNOP Comparison

TRVI vs KNOP Comparison

Compare TRVI & KNOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVI
  • KNOP
  • Stock Information
  • Founded
  • TRVI 2011
  • KNOP 2013
  • Country
  • TRVI United States
  • KNOP United Kingdom
  • Employees
  • TRVI N/A
  • KNOP N/A
  • Industry
  • TRVI Biotechnology: Pharmaceutical Preparations
  • KNOP Marine Transportation
  • Sector
  • TRVI Health Care
  • KNOP Consumer Discretionary
  • Exchange
  • TRVI Nasdaq
  • KNOP Nasdaq
  • Market Cap
  • TRVI 211.4M
  • KNOP 213.1M
  • IPO Year
  • TRVI 2019
  • KNOP 2013
  • Fundamental
  • Price
  • TRVI $4.51
  • KNOP $5.55
  • Analyst Decision
  • TRVI Strong Buy
  • KNOP
  • Analyst Count
  • TRVI 8
  • KNOP 0
  • Target Price
  • TRVI $9.31
  • KNOP N/A
  • AVG Volume (30 Days)
  • TRVI 4.0M
  • KNOP 97.9K
  • Earning Date
  • TRVI 11-06-2024
  • KNOP 12-04-2024
  • Dividend Yield
  • TRVI N/A
  • KNOP 1.88%
  • EPS Growth
  • TRVI N/A
  • KNOP N/A
  • EPS
  • TRVI N/A
  • KNOP N/A
  • Revenue
  • TRVI N/A
  • KNOP $299,790,000.00
  • Revenue This Year
  • TRVI N/A
  • KNOP $7.66
  • Revenue Next Year
  • TRVI N/A
  • KNOP $1.75
  • P/E Ratio
  • TRVI N/A
  • KNOP N/A
  • Revenue Growth
  • TRVI N/A
  • KNOP 4.75
  • 52 Week Low
  • TRVI $1.26
  • KNOP $4.94
  • 52 Week High
  • TRVI $4.60
  • KNOP $9.11
  • Technical
  • Relative Strength Index (RSI)
  • TRVI 75.02
  • KNOP 32.07
  • Support Level
  • TRVI $2.36
  • KNOP $5.36
  • Resistance Level
  • TRVI $4.60
  • KNOP $5.98
  • Average True Range (ATR)
  • TRVI 0.33
  • KNOP 0.23
  • MACD
  • TRVI 0.21
  • KNOP -0.02
  • Stochastic Oscillator
  • TRVI 92.46
  • KNOP 17.50

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

Share on Social Networks: